Drug Discovery for Neurodegeneration presented by Alzheimer's Drug Discovery Foundation
The Westin @ Times Square	New York, NY - February 5-6, 2007
General Information Speakers Program Session Synopses Registration Accommodations Sponsorships/Exhibits Acknowledgments Contact	P R O G R A M  (click here to download a PDF version) (click session title to access synopsis and click on to download PDF of presentation) MONDAY, FEBRUARY 5 7:45 – 8:30 am REGISTRATION & CONTINENTAL BREAKFAST 8:30 – 8:40 WELCOME & OPENING REMARKS Howard Fillit, MD, Executive Director, ADDF 8:40 – 9:10 PLENARY TALK An Overview of Drug Discovery for Neurodegenerative Disease Barry D. Greenberg, PhD – Neurochem, Inc. I. TARGET IDENTIFICATION & VALIDATION:  HOW OUR UNDERSTANDING OF THE BIOLOGY OF NEURODEGENERATION CAN BE EMPLOYED Chair: Linda Van Eldik, PhD, Northwestern University 9:10 – 9:30 Risk in CNS Drug Discovery J. Fred Pritchard, PhD, MDS - Pharma Services 9:30 – 9:50 Mechanism of Neurodegeneration Steven Paul, MD - Eli Lilly and Company 9:50 – 10:10 How to Decide if a Target Should be Advanced for Discovery Dale B. Schenk, PhD - Elan Pharmaceuticals 10:10 – 10:30 Target Validation in CNS Drug Discovery Barbara Sahagan, PhD - Pfizer, Inc 10:30 – 10:50 PANEL DISCUSSION 10:50 – 11:10 BREAK II. LEAD DISCOVERY: IN-VITRO MODELS OF NEURODEGENERATIVE DISEASE Chair: Ross Stein, PhD, Harvard Medical School & Brigham and Women’s Hospital 11:10 – 11:30   Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates Richard K. Harrison, PhD - Vitae Pharmaceuticals 11:30 – 11:50 Identification of Hits and Leads for Neurodegenerative Diseases: Case Studies Marcie Glicksman, PhD - Harvard Medical School 11:50 – 12:10 pm Laboratory for Drug Discovery in Neurodegeneration: A Model for Leads Discovery in Academia Ross Stein, PhD- Session Chair 12:10 – 12:30 PANEL DISCUSSION 12:30 – 1:30 LUNCH III. LEAD IDENTIFICATION & OPTIMIZATION: UNIQUE ASPECTS OF CHEMISTRY IN NEURODEGENERATIVE DISEASE Chair: D. Martin Watterson, PhD, Northwestern University 1:30 – 1:50 Hits to Leads to Drugs: What Makes a Chemical a Drug Christopher A. Lipinski, PhD – Melior Discovery 1:50 – 2:10 Principles of Medicinal Chemistry Refinement for CNS Drug Discovery Camille G. Wermuth, PharmD, PhD -Universite Pasteur Strasbourg & Prestwick Chemical, Inc 2:10 – 2:30 Design of Chemical Libraries: Focus, Diversity & Size F. Raymond Salemme, PhD, Linguagen Corp. 2:30 – 2:50 PANEL DISCUSSION 2:50 – 3:10 BREAK  IV. PRE-CLINICAL PROOF-OF-CONCEPT AND DEVELOPMENT: NEURODEGENERATIVE DISEASE Chair: Jordan Tang, PhD, Oklahoma Medical Research Foundation 3:10 – 3:30 What is Pre-Clinical Proof-of-Concept Manfred Windisch, PhD - JSW-Research 3:30 – 3:50 ADME, Pre-clinical Toxicology & Preparing for Clinical Development – Phase 1, GMP, GLP Karen L. Steinmetz, PhD, DABT- SRI International 3:50 – 4:10 Neuroimaging, Biomarkers and Surrogates in CNS Clinical Development Michael W. Weiner, MD - University of California, San Francisco 4:10 – 4:30 PANEL DISCUSSION 4:30 – 6:30 OPEN NETWORKING AND REFRESHMENTS TUESDAY, FEBRUARY 6, 2007 8:00 – 8:30 am CONTINENTAL BREAKFAST V. DRUG DELIVERY TECHNOLOGIES TO THE CNS Chair: Illana Gozes, PhD, Allon Therapeutics and Tel Aviv University 8:30 – 8:50   Characteristics of Compounds that Cross the Blood Brain Barrier (BBB) William A. Banks, MD - Saint Louis University School of Medicine 8:50 – 9:10 Analytical Methods: Measuring Diffusion into Brain Illana Gozes, PhD – Session Chair 9:10 – 9:30 Nanotech and the BBB Gabriel A. Silva, MSc, PhD, University of California, San Diego 9:30 – 9:50   Intranasal Delivery Bypasses the BBB to Target Therapeutic Agents to the CNS William H. Frey II, PhD - University of Minnesota & Regions Hospital 9:50 – 10:10 Transport Based Delivery Approaches Henry R. Costantino, PhD - Nastech Pharmaceutical Company Inc. 10:10 – 10:30 PANEL DISCUSSION 10:30 – 10:50 BREAK VI. PARTNERING & OTHER MODELS FOR ADVANCING DRUG DISCOVERY:  FINDING RESOURCES TO ADVANCE NEURODEGENERATIVE DISEASE DRUG DISCOVERY Chair: Elias Michaelis, MD, PhD, University of Kansas 10:50 – 11:10     The Role of Contract Research Organizations (CROs) in Advancing Pre-Clinical CNS Development Oppel Greeff, MD, Quintiles International 11:10 – 11:30 Contract Research Organizations Peter Schüler, MD, MPM - PRA International 11:30 – 11:50 Center-based Models in Academia Elias Michaelis, MD, PhD – Session Chair 11:50 – 12:10 pm   Resources at the National Institute of Health Neil Buckholtz, PhD - National Institute on Aging and Lorenzo Refolo, PhD - National Institute of Neurological Disorders and Stroke 12:10 – 12:30 PANEL DISCUSSION 12:30 – 1:30 LUNCH VII. BUSINESS DEVELOPMENT & TECHNOLOGY TRANSFER IN NEURODEGENERATION Chair: Richard DiRocco, PhD, Secant Pharma 1:30– 1:50 Licensing, Contracts, and Intellectual Property Dale Lombardi, PhD, Secant Pharma 1:50 – 2:10 The Role of Your Technology Transfer Office John Zawad, University of Pennsylvania 2:10 – 2:30 Developing Your Technologies to the Point of Interest & Pros and Cons of Starting Your Own Biotech in Neurodegenerative Disease Richard DiRocco, PhD- Session Chair 2:30 – 2:50 Partnering With Pharma & Biotech: What Do They Look for? Lawrence M. Zaccaro, Pfizer, Inc.        2:50 – 3:10 PANEL DISCUSSION 3:10 – 3:15 CLOSING REMARKS Howard Fillit, MD, Executive Director, ADDF     top